Key Trends and Drivers Influencing the Future of the Consumer Health Industry: The Global Rise of E-Commerce –

DUBLIN–(BUSINESS WIRE)–The “Voice of the Industry: Consumer Health” report has been added to’s offering. In the Voice of the Industry Survey series, the analyst connects with industry professionals to explore trends and innovations. This report focuses on the consumer health industry, drawing on the Voice of the Industry: Consumer Health Survey. The global briefing … [Read more…]

AIBODY Partners with Relias to Develop Next Generation of Interactive Training Materials for Medical Professionals

LONDON–(BUSINESS WIRE)–AIBODY, the world’s first Physiology-as-a-Service platform, announced today that it will partner with Relias, the United States-based healthcare education and workforce development leader, to develop an innovative range of digital study materials for professional medical training. Specializing in healthcare education solutions, Relias helps more than 11,000 organizations and 4.5 million caregivers elevate care to … [Read more…]

Dr. Reddy’s Laboratories announces the launch of the generic version of Nexavar (sorafenib) Tablets, USP, 200 mg in the U.S. market

HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–$RDY #BayerHealthCare–Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Dr. Reddy’s Sorafenib Tablets, USP, 200 mg, a therapeutic generic equivalent of Nexavar® (sorafenib) Tablets in the U.S. market following the approval … [Read more…]

PureTech Meets Milestone of Achieving Oral Bioavailability of Allopregnanolone in Healthy Adults Dosed with LYT-300

LYT-300 achieved systemic blood levels approximately nine-fold greater compared to previous reports with oral allopregnanolone.1 Allopregnanolone is a neurosteroid with proven efficacy that is currently only approved as a 60-hour intravenous infusion. LYT-300, an orally administered prodrug of allopregnanolone, is designed to be differentiated from synthetic analogs, which may not replicate the full target engagement … [Read more…]

Beckley Psytech Announces Partnership With Ksana Health, Building on Digital Strategy to Deliver Optimised Patient Outcomes

Partnership will focus on the collection and analysis of digital biomarkers to identify signs of response and relapse in upcoming Phase 2 clinical trials Beckley Psytech aims to track and improve patient experience through an integrated, digitally-assisted treatment model OXFORD, England–(BUSINESS WIRE)–Beckley Psytech Limited, a private company dedicated to addressing neurological and psychiatric disorders through … [Read more…]

PureTech Reports Results from Phase 2 Study of LYT-100-COV in Post-Acute “Long” COVID with Respiratory Complications

No treatment effect observed in this patient population; substantial improvement in 6-minute walk test seen in both placebo and active groups Study adds to growing body of data supporting strong safety and tolerability profile of LYT-100 (deupirfenidone) Company will drive LYT-100 forward in other indications, with a focus on IPF where human clinical efficacy has … [Read more…]

Children’s Hospital Los Angeles: The Best Care for Kids in California and the West Coast

U.S. News & World Report’s annual hospital survey again ranks Children’s Hospital Los Angeles among the top 10 pediatric hospitals in the nation LOS ANGELES–(BUSINESS WIRE)–#childrenshealth–Children’s Hospital Los Angeles (CHLA) continues its streak of being California’s top hospital for pediatric care and specialty services, according to U.S. News & World Report’s 2022-23 Best Children’s Hospitals … [Read more…]

Alnylam Announces FDA Approval of AMVUTTRA™ (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults

– First and Only FDA-approved Treatment Demonstrating Reversal in Neuropathy Impairment with Subcutaneous Administration Once Every Three Months – – AMVUTTRA Met Primary and All Secondary Endpoints, with Significant Improvement in Polyneuropathy, Quality of Life and Gait Speed Relative to External Placebo – – Company Expects to Launch in Early July, with Value-Based Agreements to … [Read more…]

Rockley Photonics Set to Join Russell 3000® Index

OXFORD, England & PASADENA, Calif.–(BUSINESS WIRE)–$RKLY #RKLY–Rockley Photonics Holdings Limited (NYSE: RKLY), a global leader in photonics-based health monitoring and communications solutions, announced that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2022 Russell indexes annual reconstitution, effective after the U.S. market opens on June 27, 2022, according … [Read more…]

Persad Center Announces Date for 2022 Annual Fundraising Gala, Art for Change; Launches Pilot Program to Support Artists

Funds Raised Will Support Mental Health Services for Pittsburgh’s LGBTQ+ Community PITTSBURGH–(BUSINESS WIRE)–Persad Center is hosting “Art for Change 2022” on Friday, September 9 at Stage AE on the North Shore. The event, Persad’s 35th Annual, is one of the region’s most significant art auctions. Proceeds support Persad Center’s mission of providing mental health services … [Read more…]